Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 9, 2013, Pages

  Ozakca, Isil ^a   Arioglu Inan, Ebru ^a   Esfahani, Hrag ^b   Altan, V Melih ^a   Balligand, Jean Luc ^b   Kayki Mutlu, Gizem ^a   Ozcelikay, A Tanju ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

adrenoceptors; Adrenergic stimulation; Inotropy; Nebivolol

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; FENOTEROL; FORSKOLIN; ISOPRENALINE; MESSENGER RNA; METOPROLOL; NEBIVOLOL; NORADRENALIN; PHOSPHOLAMBAN; PLACEBO; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TATA BINDING PROTEIN;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY VASCULAR RESISTANCE; DESENSITIZATION; DRUG EFFECT; EXCITATION CONTRACTION COUPLING; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HEART VENTRICLE HYPERTROPHY; INOTROPISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

Β-ADRENOCEPTORS; ADRENERGIC STIMULATION; INOTROPY; NEBIVOLOL;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-AGONISTS; ANIMALS; ATRIAL NATRIURETIC FACTOR; BENZOPYRANS; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; CORONARY CIRCULATION; ETHANOLAMINES; HEART RATE; ISOPROTERENOL; MALE; METOPROLOL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TRANSCRIPTION, GENETIC;

EID: 84878591485     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00352.2012     Document Type: Article

References (40)

1. Balligand JL. β3-Adrenoceptor stimulation on top of β1-adrenoceptor blockade "Stop or Encore?" J Am Coll Cardiol 53: 1539-1542, 2009.
2. Belge C, Sekkali B, Tavernier G, Poulier AC, Bertrand L, Vanoverschelde JL, Hilfiker-Kleiner D, Langin D, Balligand JL. Cardiomyocyte-specific overexpression of β3-adrenoceptors attenuates the hypertrophic response to catecholamines in vivo (Abstract). Circulation 116: II-148, 2007.
3. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, Roden R, Asano K, Blaxall BC, Wu SC, Communal C, Singh K, Colucci W, Bristow MR, Port DJ. Myocardial-directed overexpression of the human α1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 32: 817-830, 2000.
4. + pump by reversal of an inhibitory oxidative modification. Circulation 122: 2699-2708, 2010.
5. Calvert JW, Condit ME, Aragón JP, Nicholson CK, Moody BF, Hood RL, Sindler AL, Gundewar S, Seals DR, Barouch LA, Lefer DJ. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of β3-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res 108: 1448-1458, 2011.
6. Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, Cheng CP. Upregulation of functional β3-adrenergic receptor in the failing canine myocardium. Circ Res 89: 599-606, 2001.
7. Dincer UD, Bidasee KR, Güner S, Tay A, Ozcelikay AT, Altan VM. The effect of diabetes on expression of β1-, β2-, and β3-adrenoreceptors in rat hearts. Diabetes 50: 455-461, 2001.
8. de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Involvement of the β3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol 42: 232-236, 2003.
9. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL. Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol. Circulation 112: 1198-1205, 2005.
10. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in α1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059-7064, 1999.
11. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ, Anderson ME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133: 462-474, 2008.
12. Fang Y, Nicol L, Harouki N, Monteil C, Wecker D, Debunne M, Bauer F, Lallemand F, Richard V, Thuillez C, Mulder P. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol. J Mol Cell Cardiol 51: 168-176, 2011.
13. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; Investigators SENIORS. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215-225, 2005.
14. Gauthier C, Laurent K, Charpentier F, Drouin E, Chevallier JC, Le Marec H. Endomyocardial biopsies: a new approach for studying the electrical and mechanical properties of human ventricular myocardium. J Mol Cell Cardiol 26: 1267-1271, 1994.
15. Hagemann D, Xiao RP. Dual site phospholamban phosphorylation and its physiological relevance in the heart. Trends Cardiovasc Med 12: 51-56, 2002.
16. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 16: e1-e194, 2010.
17. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 85: 339-343, 1988.
18. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 110: 1646-1660, 2012.
19. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-adrenergic signaling in heart failure? Circ Res 93: 896-906, 2003.
20. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102: 470-479, 2000.
21. McMartin L, Summers RJ. Functional analysis of desensitization of the β-adrenoceptor signalling pathway in rat cardiac tissues following chronic isoprenaline infusion. Br J Pharmacol 127: 1012-1020, 1999.
22. Métrich M, Lucas A, Gastineau M, Samuel JL, Heymes C, Morel E, Lezoualc=h F. Epac mediates β-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res 102: 959-965, 2008.
23. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK, Champion HC, Bedja D, Gabrielson KL, Chen J, Xia Y, Hale AB, Channon KM, Halushka MK, Barker N, Wuyts FL, Kaminski PM, Wolin MS, Kass DA, Barouch LA. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the β3-adrenoreceptor. J Mol Cell Cardiol 47: 576-585, 2009.
24. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of β3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103: 1649-1655, 2001.
25. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mülsch A, Li H, Förstermann U, Münzel T. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48: 677-684, 2006.
26. Pandey D, Gratton JP, Rafikov R, Black SM, Fulton DJ. Calcium/ calmodulin-dependent kinase II mediates the phosphorylation and activation of NADPH oxidase 5. Mol Pharmacol 80: 407-415, 2011.
27. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
28. Rozec B, Quang TT, Noireaud J, Gauthier C. Mixed β3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br J Pharmacol 147: 699-706, 2006.
29. Shibata M, Takeshita D, Obata K, Mitsuyama S, Ito H, Zhang GX, Takaki M. NHE-1 participates in isoproterenol-induced downregulation of SERCA2a and development of cardiac remodeling in rat hearts. Am J Physiol Heart Circ Physiol 301: H2154-H2160, 2011.
30. Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I, Mohmand W, Akbar R, Bahlmann F, Besler C, Schaefer A, Hilfiker-Kleiner D, Lüscher TF, Balligand JL, Drexler H, Landmesser U. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade. J Am Coll Cardiol 57: 601-611, 2011.
31. Sucharov CC, Mariner PD, Nunley KR, Long C, Leinwand L, Bristow MR. A α1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol 291: H1299-H1308, 2006.
32. van den Bosch BJ, Lindsey PJ, van den Burg CM, van der Vlies SA, Lips DJ, van der Vusse GJ, Ayoubi TA, Doevendans PA, Smeets HJ. Early and transient gene expression changes in pressure overload-induced cardiac hypertrophy in mice. Genomics 88: 480-488, 2006.
33. van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, Investigators SENIORS. B-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53: 2150-2158, 2009.
34. 2+/calmodulin kinase signaling pathway. Circ Res 95: 798-806, 2004.
35. Whaley-Connell A, Habibi J, Johnson M, Tilmon R, Rehmer N, Rehmer J, Wiedmeyer C, Ferrario CM, Sowers JR. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol 30: 354-360, 2009.
36. Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Yao L, Nagai Y, Fujisawa Y, Miyatake A, Abe Y. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 65: 230-238, 2005.
37. Zhang GX, Ohmori K, Nagai Y, Fujisawa Y, Nishiyama A, Abe Y, Kimura S. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol 42: 804-811, 2007.
38. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11: 409-417, 2005.
39. Zhou X, Ma L, Habibi J, Whaley-Connell A, Hayden MR, Tilmon RD, Brown AN, Kim JA, Demarco VG, Sowers JR. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 55: 880-888, 2010.
40. 2+/calmodulin kinase II. J Clin Invest 111: 617-625, 2003.